What is he best known for?
The fields of study he is best known for:
- Cancer
- Internal medicine
- Immune system
His primary scientific interests are in Immunology, Molecular biology, In vivo, Interleukin 2 and Cytotoxic T cell.
His study ties his expertise on Cancer research together with the subject of Immunology.
His Molecular biology research includes themes of Affinity label, Alpha, Virology, Genetic enhancement and Cytolysis.
He combines subjects such as Biochemistry, Interferon gamma, Cytotoxicity and Pharmacology with his study of In vivo.
His Interleukin 2 study combines topics from a wide range of disciplines, such as Toxicity, Lymphokine, Gastroenterology and Lymphokine-activated killer cell.
His Antigen research is multidisciplinary, incorporating elements of Antibody, Monoclonal antibody and Antibody-dependent cell-mediated cytotoxicity.
His most cited work include:
- Interferon-induced indoleamine 2,3-dioxygenase activity in human mononuclear phagocytes. (169 citations)
- Homozygous deletions that simultaneously eliminate expressions of class I and class II antigens of EBV-transformed B-lymphoblastoid cells. I. Reduced proliferative responses of autologous and allogeneic T cells to mutant cells that have decreased expression of class II antigens (165 citations)
- Homozygous deletions that simultaneously eliminate expressions of class I and class II antigens of EBV-transformed B-lymphoblastoid cells. I. Reduced proliferative responses of autologous and allogeneic T cells to mutant cells that have decreased expression of class II antigens (165 citations)
What are the main themes of his work throughout his whole career to date?
His primary areas of investigation include Immunology, Cancer research, Immunotherapy, Monoclonal antibody and Interleukin 2.
His studies in Immunology integrate themes in fields like Cytotoxic T cell and In vivo.
In his research, Bone marrow is intimately related to T cell, which falls under the overarching field of Cancer research.
His Monoclonal antibody research incorporates themes from Receptor and Neuroblastoma.
His research in Interleukin 2 intersects with topics in Lymphokine, Lymphokine-activated killer cell and Lymphocyte.
His study in Antigen is interdisciplinary in nature, drawing from both Molecular biology and Virology.
He most often published in these fields:
- Immunology (48.41%)
- Cancer research (26.43%)
- Immunotherapy (26.43%)
What were the highlights of his more recent work (between 2016-2021)?
- Immunotherapy (26.43%)
- Cancer research (26.43%)
- Neuroblastoma (10.83%)
In recent papers he was focusing on the following fields of study:
Paul M. Sondel mainly investigates Immunotherapy, Cancer research, Neuroblastoma, Internal medicine and Antibody.
Paul M. Sondel has begun a study into Immunotherapy, looking into Immune system and Immunology.
His work deals with themes such as Alpha and Glycan, which intersect with Immunology.
His study in the field of Melanoma also crosses realms of In situ.
His Internal medicine research integrates issues from Gastroenterology, Oncology and Monoclonal.
His studies deal with areas such as In vivo, Solid tumor, Pharmacology and Antigen as well as Monoclonal antibody.
Between 2016 and 2021, his most popular works were:
- Insights from immuno-oncology: the Society for Immunotherapy of Cancer Statement on access to IL-6-targeting therapies for COVID-19. (43 citations)
- A Comprehensive Safety Trial of Chimeric Antibody 14.18 With GM-CSF, IL-2, and Isotretinoin in High-Risk Neuroblastoma Patients Following Myeloablative Therapy: Children's Oncology Group Study ANBL0931. (36 citations)
- Evaluating natural killer cell cytotoxicity against solid tumors using a microfluidic model. (21 citations)
In his most recent research, the most cited papers focused on:
- Cancer
- Internal medicine
- Immune system
The scientist’s investigation covers issues in Internal medicine, Oncology, Immunotherapy, Neuroblastoma and Cancer research.
His Internal medicine research is multidisciplinary, relying on both Gastroenterology and Monoclonal.
His research integrates issues of Clinical trial, Refractory, Dinutuximab, Virus and Pneumonitis in his study of Oncology.
As a part of the same scientific family, Paul M. Sondel mostly works in the field of Immunotherapy, focusing on Antibody and, on occasion, Lipopolysaccharide, Cancer cell, Cytolysis and Cell biology.
His Neuroblastoma research incorporates elements of Solid tumor, Monoclonal antibody and Phases of clinical research.
His study explores the link between Cancer research and topics such as Immune system that cross with problems in Natural killer cell and In vitro.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
